$8.22
2.49% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
BE0974358906
Symbol
NYXH

Nyxoah SA Stock price

$8.22
-1.28 13.47% 1M
-2.05 19.96% 6M
+3.58 77.16% YTD
+3.34 68.44% 1Y
-15.26 64.99% 3Y
-11.28 57.85% 5Y
-11.28 57.85% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.21 2.49%
ISIN
BE0974358906
Symbol
NYXH
Sector

Key metrics

Market capitalization $282.44m
Enterprise Value $229.27m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 41.61
P/S ratio (TTM) P/S ratio 51.26
P/B ratio (TTM) P/B ratio 2.42
Revenue growth (TTM) Revenue growth 35.22%
Revenue (TTM) Revenue $5.51m
EBIT (operating result TTM) EBIT $-56.46m
Free Cash Flow (TTM) Free Cash Flow $-54.17m
Cash position $79.21m
EPS (TTM) EPS $-1.86
P/E forward negative
P/S forward 46.40
EV/Sales forward 37.88
Short interest 0.28%
Show more

Is Nyxoah SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Nyxoah SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Nyxoah SA forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Nyxoah SA forecast:

Buy
78%
Hold
22%

Financial data from Nyxoah SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5.51 5.51
35% 35%
100%
- Direct Costs 5.02 5.02
34% 34%
91%
0.49 0.49
58% 58%
9%
- Selling and Administrative Expenses 23 23
16% 16%
421%
- Research and Development Expense 31 31
25% 25%
560%
-54 -54
21% 21%
-972%
- Depreciation and Amortization 2.91 2.91
28% 28%
53%
EBIT (Operating Income) EBIT -56 -56
21% 21%
-1,025%
Net Profit -58 -58
18% 18%
-1,044%

In millions USD.

Don't miss a Thing! We will send you all news about Nyxoah SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nyxoah SA Stock News

Neutral
Seeking Alpha
7 days ago
Nyxoah S.A. (NASDAQ:NYXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and IR Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Adam Maeder - Piper Sandler Joe Federico - Stifel Suraj Kalia - Oppenheimer Ross Osborn - Cantor Fitzgerald David Rescott - Baird Operator Good day.
EQS
9 days ago
Bestimmte Aussagen, Überzeugungen und Meinungen in dieser Pressemitteilung sind zukunftsorientiert und spiegeln die aktuellen Erwartungen des Unternehmens bzw. der Direktoren oder der Geschäftsleitung des Unternehmens hinsichtlich des Genio®-Systems; geplanter oder laufender klinischer Studien mi...
More Nyxoah SA News

Company Profile

Nyxoah SA engages in the research and development, manufacture and sale of medical devices. It focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Its lead solution platform is based on the Genio system, a validated, user-centered, neurostimulation therapy for obstructive sleep apnea (OSA). The company was founded by Robert Taub and Adi Mashiach on July 15, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Head office Belgium
CEO Olivier Taelman
Employees 146
Founded 2009
Website www.nyxoah.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today